International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

A Range of Biological Medications Utilized for the Treatment of Fungal Infections

Rupam Kumar[1], Akshat Pratap Singh[2], Mr. Shubham Garg[3], Ramanpreet Kaur[4], Mr. Rajat Koundal[5]

[1,2,4]College of Pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India-147301
[3]Assistant professor, College of pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India-147301
[5]Associate professor, College of pharmacy, RIMT University, Mandi Gobindgarh, Punjab, India-147301

ABSTRACT

A worldwide health concern, fungal infections impact more than one billion people annually, and their occurrence is steadily rising due to environmental changes, an increase in impaired populations, and antifungal resistance. Because of their high rates of resistance and death, fungi such as Aspergillus fumigatus, albicans Candida, Candida auris, & Cryptococcus neoformans, for example, have been designated as important priority by the WHO. The four medication classes used in current antifungal therapies—polyenes, azoles, echinocandins, and flucytosine—are hampered by toxicity as well as resistance, and their molecular targets are restricted since the eukaryotic state of the fungal infections is so like that of the host. The creation of vaccinations that target certain common antigens, such as β-1,3-glucan, immunotherapeutics, which includes the utilization of monoclonal antibodies, like mAb 2G8 as well as efungumab, and novel drug discoveries are some of the potential strategies. By identifying factors affecting virulence and metabolic pathways as potential targets for intervention, omics techniques (genomics, proteomics, and metabolomics) are revolutionizing fungal research. However, host diversity and fungal immune evasion further complicate the vaccine development process. Potential creation of antifungal chemicals from medicinal plants and marine species is also being investigated. Multidisciplinary action is required to develop safe and efficient treatments for high-risk groups, support diagnostics, and launch an attack against resistance mechanisms.

Keywords: - Fungal infections, Antifungal resistance, Immunotherapeutics, Omics technologies, Vaccine development

INTRODUCTION

Fungal infections are a serious and often overlooked public health issue. About a billion individuals are impacted by them, and the symptoms they cause range from allergic reaction to serious systemic diseases to local mucocutaneous infections (1,2). Many more people are consequently at risk of developing fungal illnesses because of changes in the global social and economic and environmental landscape as well as an increase in the number of immuno-compromised persons (1, 3). This necessitates a rapid and ongoing reaction to combat the lethal microorganisms, as does the fact that clinical procedures are based on the utilization of only 4 classes of systemically active antifungals and that antifungal resistance to these drugs is developing in practice (2). Research and policy initiatives to alleviate fungal illness have thankfully

gained momentum in response to recent calls to action, such as the UN World Health Organization's creation of the Fungal Priority Infectious Agents List for the First Time (2, 4, 5). Aspergillus fumigatus, Cryptococcus neoformans, and two species of Candida—Candida albicans and Candida auris—are classified as "critically priority" on this list. Because of their rates of antifungal resistance, mortality, incidence, sequelae, accessibility to diagnosis, treatability, and cost, these organisms were given critical attention. Organ transplant recipients, hematologic patients in need of transplants of stem cells, AIDS patients, diabetics, victims of burns, patients with neoplastic diseases, patients on immunosuppression for the management of inflammatory diseases, and other individuals with chronic respiratory illnesses are among the groups most at risk of acquiring an opportunistic fungal infection (6). Invasive candidiasis (IC) accounts for over 70% of all IFIs worldwide, with cryptococcosis (20%) as well as aspergillosis (10%) following closely behind (7,8). 25% of people worldwide suffer from these superficial fungal infections, with skin mycoses being one of the most common illnesses (9). While most infections respond well to conventional therapy, recurrence is common and some conditions, such as onychomycosis, have a relatively high failure incidence of 25% (10). The dermatological condition resistant to terbinafine has recently been observed in India, indicating an increase in resistance to conventional therapy (11). Several negative side effects, including liver damage and unintended drug interactions, have also been linked to conventional medications (12). In clinical and agricultural contexts, antifungal resistance is becoming a greater problem (13,14). The impact of extensive antifungal usage on agriculture cannot be overlooked, even if the discovery of novel antifungal medications has been a major priority in recent years. The same antifungal medications used for human's medicine are frequently utilized to treat fungi which cause plant illnesses (15). The application of azoles to treat fungal diseases in plants including maize, wheat, and barley is one such instance (16). Azole-resistant strains of plant- pathogenic fungi have emerged because of the extensive usage of azoles in agriculture. These resistant strains can spread to other plants and, in certain situations, to people who eat the crops (17). In recent years, azole-resistant strains and acquired resistance to echinocandins have been seen in large regions of Europe (19). Public health is at risk due to the uncontrolled use of anti-fungal medications. The development of new and more effective alternatives has become increasingly difficult for academics and pharmaceutical businesses due to widespread antifungal resistance. Furthermore, the variety of individuals at risk for these invasive infections has increased to an unprecedented level. Examples of these patients include those who have received stem cell transplantation, those who suffer from severe influenza, or those who have chronic pulmonary obstructive disease (20,21). Selecting the right kind of treatment for these kinds of individuals has grown increasingly challenging. It is imperative that efforts be made to develop new medications that do not have resistance mechanisms. According to references (22,23), a rise in the quantity of fungal infections recorded may be ascribed to both improved detection techniques and a rise in the number for patients at risk. Antifungal medication development has historically been quite limited. There are now four main groups of antifungal medications: flucytosine, azoles, polyenes, and echinocandins (24). Drug resistance, variable pharmacokinetics, toxicity, restricted accessibility, and drug-drug interactions are among the drawbacks of these current pharmacological classes (25). Clarifying the biochemical systems particular to fungi as reference targets to drug development becomes more crucial given the complexity of antifungal research and the fact that fungus and humans share many eukaryotic processes, which reduces the number of targets that are pathogen specific. Various innovative therapeutics with various mechanisms and those medications under research investigation are reviewed in this study.

CHALLENGES OF THE CURRENT ANTI-FUNGAL DRUGS

The emergence of antifungal resistance is one of the main obstacles in the development of antifungal medications. It is claimed that the development of this resistance is outpacing the discovery of antifungals. Due mostly to their fast reproduction and genomic flexibility, fungi produce variations very quickly (26). Fungicide resistance is driven by three main evolutionary processes, which are briefly depicted in Figure 1: quick reproductive output, heritable variation, and differential survival. The fact that fungal infections are more closely related to their hosts is undermining the development of antifungal drugs. These shortcomings are discussed by Gillian M. Smith; there are significant similarities between fungi as well as their human hosts in important biological processes as well as cell biology processes. Consequently, Saccharomyces cerevisiae was recognized as a legitimate model eukaryotic organism. As a result, many little substances that are harmful to the yeast are also harmful to people. Therefore, it is interesting that the three primary groups of antifungal medications mostly target fungal-specific structures. The development of new medications has been hampered by a number of issues with the design of clinical trials for novel antifungal medicines, in addition to scientific barriers to the adoption of novel lead substances (28). Nonetheless, these fundamental issues complement the well-known scientific, legal, and financial difficulties related to the creation of anti-infectives (29).



Fig-1: Recognizing the factors that influence fungal adaptability to antifungal treatment

Table-1: An overview on natural antifungal substances created by marine life (30,31)

Marine Organism	Source Organism	Compound Type	Compound Name	Spectrum of Activity
Bacteria				

Marine Organism	Source Organism	Compound Type	Compound Name	Spectrum of Activity
(30%)				
	Bacillus licheniformis	Glycolipid	Ledoglucomide C, Iedoglycolipid	*Aspergillus niger, Rhizoctonia solani, Botrytis cinerea*
	Bacillus subtilis	Lipopeptide	Gageopeptides A-D	*R. solani, P. capsici, B. cinerea, C. acutatum*
	Actinoalloteichus sp. NPS702	Macrolide	Neomaclafungins A-I	*Trichophyton mentagrophytes*
	Streptomyces sp.	Peptide	Mohangamide A	*Candida albicans*
	Bacillus marinus	Macrolide	Macrolactins T and B	*Pyricularia oryzae, Alternaria solani*
	Tolypothrix	Lipopeptide	Hassallidin A	*Aspergillus fumigatus, C. albicans*
	Chondromyces pediculatus	Peptide	Pedein A	*Rhodotorula glutinis*
Fungi (15%)				
	Stagonosporopsis cucurbitacearum	Alkaloid	Didymellamide A	*Cryptococcus neoformans, C. albicans, C. glabrata*
	Aspergillus sclerotiorum	Peptide	Sclerotide B	*C. albicans*
	Penicillium bilaiae MA-267	Sesquiterpene	Penicibilaenes A and B	*Colletotrichum gloeosporioides*

Marine Organism	Source Organism	Compound Type	Compound Name	Spectrum of Activity
Sponge (35%)				
Corals (5%)	*Theonella swinhoei*	Peptide	Theonegramide, Theonellamide G, Cyclolithistide A	*C. albicans*
	Halichondria cylindrata	Peptide	Halicylindramide D and E	*Mortierella ramanniana*
	Siliquariaspongia mirabilis, Theonella swinhoei	Peptide	Theopapuamide A, B, C	*C. albicans*
	Jaspis johnstoni	Peptide	Jasplakinolide	*C. albicans, C. pseudotropicalis, C. parapsilosis*
	Monanchora arbuscular	Alkaloid	Batzelladine L	*Aspergillus flavus*
	Xestospongia muta	Furan	Mutafuran D	*Cryptococcus neoformans var. grubii*
	Clavelina oblonga	Alkanol	(2S,3R)-2-aminododecan-3-ol	*C. albicans ATCC 10231, C. glabrata*
Sea Cucumbers (6%)	*Stichopus variegates*	Triterpene glycoside	Variegatuside D	*C. albicans, C. pseudotropicalis, C. parapsilosis, Microsporum gypseum*
Algae (9%)	*Caulerpa racemos*	Xylene	Caulerprenylol B	*Trichophyton rubrum*

Table 2: Medicinal plants are categorized based on the bioactive substances that have antifungal properties.

Bioactive Compound	Plant Source	Chemical Constituent for Antifungal Activity	Activity/Findings
Polyphenols	*Baseonema acuminatum*	Three phenolic compounds: 1-galloyl-β-D-glucopyranosyl-(1→4)-2-methoxy-5-(1',2',3'-trihydroxypropyl) phenyl-1-O-(6''-galloyl)-β-D-galactopyranoside, 2-methoxy-5-hydroxymethyl-phenyl-1-O-(6''-galloyl)-β-D-glucopyranoside, and β-D-glucopyranoside	Antifungal activity against *Candida albicans* (32)
	Cuban propolis	New polyisoprenylated benzophenone	Significant antibacterial and antifungal properties against bacteria and yeasts (33)
	Garcinia mangostana	3-hydroxy-4-geranyl-5-methoxybiphenyl (geranylated biphenyl derivative)	Potent antifungal activity along with other biological functions (34)
	Isolona cauliflora and *Monodora angolensis*	Prenylindoles	Exhibited antimalarial and antifungal properties (35)
	Lycium chinense	Dihydro-N-caffeoyltyramine, trans-N-feruloyloctopamine, trans-N-caffeoyltyramine, cis-N-caffeoyltyramine	Reported antifungal activity (36)
	Toronia toru	[(3R)-3,4-dihydroxy-2-methylenebutanoyl] 4-Hydroxyphenyl-6-O-D-	Primary antibacterial constituent with antifungal effects (37)

Bioactive Compound	Plant Source	Chemical Constituent for Antifungal Activity	Activity/Findings
		glucopyranoside	
Flavonoids	*Artemisia giraldii*	Hispidulin and belamcanidin (flavones)	Inhibited growth of human pathogenic fungi (38)
	Aquilegia vulgaris	5-dihydroxy-4-methoxyflavone 6-C-glucoside (isocytisoside)	Antimicrobial action against *Aspergillus niger* (39)
	Adina cordifolia	3,4',5,7-tetraacetyl quercetin (flavon)	Moderate antifungal efficacy against *Cryptococcus neoformans* and *Aspergillus fumigatus* (40)
	Hildegardia barteri	2-hydroxy maackiain (isoflavone)	Antifungal properties (41)
Alkaloids	*Aniba panurensis*	6,8-didec-(1Z)-enyl-5,7-dimethyl-2,3-dihydro-1H-indolizinium	Effective against drug-resistant *Candida albicans* strains (42)
	Corydalis longipes	1-methoxyberberine chloride and N-methylhydrasteine hydroxylactam	Strong antifungal effectiveness (43)

IMMUNOTHERAPY

To eliminate fungal infections, immunotherapy is a novel and promising strategy for modifying the host immune response and boosting both adaptive and innate immune responses. Recombinant growth factors along with cytokines, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, & antibody usage are all used in immunotherapy treatments to fungal infections. Cell therapy, which introduces adaptive as well as innate immune cells to favorably guide the body's immune system against the offending fungus, may also be beneficial for people with immuno-compromised conditions. Antifungal antibodies or antifungal immunotherapy that is passive will form the foundation of this review. Reviews of various immunotherapy strategies can be found elsewhere (44). There are currently just two antifungal antibodies in clinical development. A monoclonal antibody called mAb 2G8 attaches itself to laminarin, which is mostly made up of β-glucans. It prevents the development and capsular formation of both Candida albicans & Cryptococcus neoformans by binding to their walls (45). Mambro et al. have reported the development of a new humanized monoclonal antibody derived from mAb 2G8 that detects

β-1,3 glucans from pathogenic fungi, including Candida spp. (46). In vitro, the latter had potent activity against Candida auris. Heat shock protein 90 (HSP90) is the target of the single-chain variable-fragment antibody efungumab (mycograb). In clinical studies, efungumab was assessed in combination with amphotericin B as well as was linked to better survival and decreased death in individuals infected with Candida. It should be mentioned that efungumab was evaluated in research studies in patients having breast cancer who were receiving docetaxel (NCT00217815). The anti-fungal antibody is coupled to radioisotopes in radio-immunotherapy, which precisely produces fungicidal rays in fungal cells, in addition to the antifungal antibodies themselves (47). In cases of drug-resistant Cryptococcus neoformans infection, this approach has demonstrated encouraging outcomes (47).

Immunotherapeutic Strategies Against Fungal Infections

Numerous immunotherapeutic approaches have been examined recently, both at the host and pathogen levels, with the goal of preventing or treating fungal infections. Regarding the host, these tactics include utilizing fungal components to manipulate the immune system of the host (e.g., vaccination); specifically stimulating both general and specific immune responses related to fungi, such as T cells, antibodies, and phagocytes; and stimulating auxiliary immune response components, such as cytokines/chemokines along with AMPs (antimicrobial peptides), (48). Almost host-independent, the pathogen-based processes rely on comparable strategies, such as the use of synthetic AMPs and monoclonal antibodies (mAbs). They also include the use for biological agents that, either directly or through the complement system, interfere with the growth and operation of pathogenic fungal molecules. A selective attack on these agents based on immunological problems of any host, especially humans, in which their have been cultured is made possible by their differences regarding host safety (47). However, these therapies are still in the early phases of research for human fungal infections, while they are actually well established for bacterial and viral infections (49). Eukaryotic bacteria have a low degree for molecular similarities to their hosts, except from hypersensitivity against fungal infections. This results in a multitude of distinct antigens that may either trigger a host immune reaction or be used as possible vaccine candidates (49). The majority of fungi have developed a way to get past the host's defenses. The main constituent of the neoformans Cryptococcus (C. neoformans) polysaccharides capsule, glucuronoxylomannan (GXM), which has been shown to have immunosuppressive qualities, is arguably the most researched. Cellular-based treatment, interferons, and vaccinations are examples of adjuvants that may improve the effectiveness of antifungal medications against their target species. In conclusion, there are disadvantages such potential toxic effects, acquired or intrinsic resistance, heightened immune system responses, inflammation cascades, including supersession by stain replacement, much like any other antifungal agent. For example, the administration of a mouse-derived anti-Cryptococcus GXM monoclonal antibodies associated with 18B7 mAb during the phase I evaluation of immunotherapy resulted in unfavorable and unexpected outcomes (50).

THE ROLE OF VACCINES IN PREVENTING FUNGAL INFECTIONS

The best way to prevent sickness is by vaccination (51). Due to the complexity of fungal cellular structures and immune evasion techniques, which include chitin and β-1,3-glucan with various compounds, developing vaccines against fungal diseases has proven more challenging than developing vaccines against bacterial and viral pathogens (52). Strong cell-mediated immunity would likely be necessary for an effective immunization against any invasive mycosis. Both Th1 & Th17 responses are hallmarks of this type of immunity, which increases the host's phagocytic capacity and enhances fungus clearance. A thorough search for vaccine antigens can uncover a wide variety of possible targets for study by extending

beyond virulence factors (53). It is highly improbable that a single, universal fungal vaccine would ever be created due to the numerous obstacles that successful anti-fungal vaccine research faces, including host susceptibility variation and different fungal infection pathways. Since no one antigen may provide widespread protection, such indoor vaccination is most likely never going to be possible. Therefore, a tailored vaccination approach that takes into account the distinct host-fungus interactions and pathogenic mechanisms of each major fungal pathogen is probably needed (54). The fact that several antigens have been used in the development of various fungal vaccines is probably related to the difficulties in creating a universal vaccination. Nonetheless, it has been noted that the preservation of certain chemicals in fungus cell walls & plasma membranes offers a chance to create a vaccine that is generally protective. In order to provide protection against a variety of mycoses and possibly even illnesses brought on by different microorganisms, shared antigens among many fungal infections may act as a common target (55). For instance, a conjugate vaccine that combines diphtheria toxoid and β-1,3-glucan has demonstrated effectiveness against a range of fungal infections by offering protection against both candidiasis and aspergillosis (56). Additionally, vaccines against some of the most prevalent organisms that cause invasive fungal infections, such as Aspergillus, Cryptococcus, and Candida, are presently being developed (57). The creation of vaccines based on recombinant proteins may be an intriguing path. To help the immune system identify and eliminate the target fungal infection, they include particular fungal antigens. Preclinical research and early-stage clinical trials have indicated promise in the case of NDV-3A, which targets Candida albicans and Staphylococcus aureus, a bacterium that causes a number of skin diseases, respiratory infections, including food poisoning (58). Another viable option that has shown promise in animal models (59) and is anticipated to be considered for human trials soon is the Cryptococcus neoformans vaccine. Despite the fact that there are currently no effective fungal vaccinations, these advancements represent a significant step toward preventing infections caused by fungi in high-risk populations. Targeting Als3p, a crucial part of the Candida albicans cell wall, is another goal being investigated, with promising first findings (60). These innovative methods are the key to creating more effective fungal vaccinations. Additional information on vaccines may be obtained from Riveria et al., 2022 (61). The creation of these vaccinations for fungal illnesses is offering a little optimism for more potent preventative measures, despite several obstacles. Although the creation of vaccines has been complicated by the intricacy of fungal cell makeup & immune evasion mechanisms, certain viable candidates are continuing to show positive outcomes. Developing common fungal antigens, such β-1,3-glucan, might improve defense against a range of infections. However, considering the variety of fungal diseases and host reactions, a universal vaccination seems implausible. Future research should accelerate the practical implementation of any such vaccines, particularly in high-risk groups, as well as the improvement of immunologic response techniques and antigen selection. Therefore, it is imperative that fungal vaccination be developed and supported in order to address current challenges and lessen the prevalence of fungal diseases worldwide.

VACCINE PLANS FOR FUNGAL INFECTIONS

Table 3: Three primary fungal vaccination plans: advantages and disadvantages (62,63).

Vaccine Type	Key Advantages	Key Limitations
Killed-Attenuated	- Presents multiple antigens for stronger	- Potential infection or excessive

Vaccine Type	Key Advantages	Key Limitations
Vaccine	immune activation - Triggers diverse immune responses, including antibody and non-CD4+ T cell pathways	inflammation risk - Not suitable for immunocompromised individuals
Conjugate Vaccine	- Targets both sugar (glycan) and protein antigens - No need for adjuvants - Safer for immunocompromised patients than live vaccines	- T cell effectiveness depends on HLA genetic makeup
Recombinant (Subunit) Vaccine	- Strongly activates protective Th cell responses - Safer for immunocompromised individuals than live vaccines	- T cell responses vary based on HLA type

OMICS TECHNOLOGIES FOR FUNGAL INFECTION PREVENTION

The emergence of omics technologies, such as proteomics, metabolomics, and genomes, has fundamentally changed our knowledge of fungal biology and presented new avenues for preventing fungal infections (64,65). These technologies allow researchers to analyze fungal diseases at a molecular level, which may provide several targets for the creation of new antifungal treatments and vaccines (66). To define the virulence determinants and drug resistance genes, for instance, genomics has revealed important information on the genomic blueprint of fungal pathogens (67). Fungal proteins implicated in host-pathogen interaction have been identified using proteomics, and these proteins might serve as targets for therapeutic intervention and vaccine development (68). Furthermore, the utilization of metabolomics provided insight into the metabolic pathways that fungi employ to survive as new targets for antifungal drugs (69). Investigators will be able to better the problems posed by drug-resistant organisms and provide a more beneficial avenue for prophylactic strategies against fungal infections by integrating other omics data. State-of-the-art mass spectrometry techniques, including hydrophilic interaction liquid chromatography–mass spectrometry (HILIC-MS) for focused analysis of phospholipid metabolism and ultrahigh-performance fluid chromatography combined with quadruple, time-of-flight mass spectrometry (UHPLC-Q-TOF-MS), were used in an integrated approach to conduct comprehensive metabolomic studies recording antifungal resistance in Candida albicans. With an apparent change in the associated metabolic pathways observed in amino acids, sphingolipid, along with phospholipid metabolism, this infrastructure identified a broad range of metabolite biomarkers that are willing to react drugly and link with resistance mechanisms (70). Furthermore, the integration of transcriptomics and epigenomics has greatly advanced our comprehension of intricate cellular dynamics. An increasing amount of data from many sources suggests that immune cells are metabolically adaptive, adjusting their responses to meet specific defense requirements by coordinating the actions of metabolic networks and epigenetic regulators (71,72). For example, several distinct immune reactions to fungus infections have been clarified with the

use of such current advancements in omics research. According to de Jesús-Gil et al. (2021) (73), C. albicans, for example, induces IL-17-mediated immunity, especially in psoriasis patients. Therefore, IL-17 dependency—the component of inflammation—is significant. These results are therapeutically useful in relation to the identification of therapy targets. Analyzing the Th1-mediated immune system reaction towards A. fumigatus antigens of fungal renown in respiratory tract infections among immunocompromised individuals was the goal of Stuehler et al. (2015) (74). The development of specialized and efficient therapies will benefit from the capacity to identify these specific immune responses. The comprehensive study of these intricate relationships between fungus and the immune system is gradually incorporating state-of-the-art omics technologies, such as transcriptomics, proteomics, metabolomics, and genomes (65). New fungal antigens with immunological targets can be found by utilizing these strategies, creating new opportunities for the creation of innovative vaccines along with immunotherapy (75). Additionally, this information lays the groundwork for adoptive T-cell transplant treatments, which promise to treat fungal infections by genetically modifying immune cells to increase their anti-fungal effectiveness (76). However, a variety of obstacles impede the potential of omics techniques for fungal prevention. One of these is the complexity of fungal genomes, which makes data interpretation challenging. Like proteomics, metabolomics, and genomics, this high-throughput approach produces vast volumes of data that need sophisticated bioinformatics tools for interpretation. This has already shown to be a hurdle with this high quantity's application (64,65). Many investigators cannot afford it, particularly in low-resource environments like Africa, because it is costly alongside to the high-cost consequences associated with omics technology (77). Finally, there are certain limitations due to ethical issues about data protection and platform standards (78).

CONCLUSION

Immunocompromised populations as well as antifungal resistance with few available treatments are contributing to an escalating worldwide health concern. As demonstrated by WHO's famous critical pathogen list, albicans Candida, Candida auris, A. fumigatus, & Cryptococcus neoformans highlighted the urgent need for novel therapies. Current antifungal drugs have a limited biological scope, target fungal cells with considerable toxicity, and are ineffective against adaptive mycophagic resistance. Immunotherapy, using monoclonal antibodies, like mAb 2G8 also efungumab, also immunization against basic fungal antigens like β-1,3-glucan are examples of potential innovative therapies. However, fungal immune evasion methods often impede these approaches. New fields of fungal biology pertaining to the discovery of drug targets especially resistance mechanisms are defined by omics technology (genomics, proteomics, and metabolomics). The maritime environment combined medicinal plants will yield new antifungal chemicals. Threats to immunotherapy, vaccines, rest-drug development, and, lastly, omics-driven precision medicine should be addressed in a coordinated manner. Effective diagnosis, treatment approaches, and preventative measures for high-risk groups require close collaboration between researchers, legislators, and healthcare professionals. The majority of fungal diseases will continue to increase sharply in consequence if financing and creative stimulation are not sustained. The public health field will suffer greatly as a result.

FUTURE PERSPECTIVES

Due to limited treatment options and growing antifungal resistance, new and multifaceted approaches were required. Future research must concentrate on developing novel antifungal medications with novel

modes of action, identifying fungal-specific targets using genomes, proteomics, and metabolomics. Although further clinical confirmation is needed, immunotherapy—particularly monoclonal antibody and adoptive T-cell therapy—shows great promise, particularly in the immunocompromised population. To give broad-spectrum protection, vaccines should target conserved fungal antigens like β-1,3-glucan, but they may also have limits because of host diversity as well as pathogen evasion. The entire landscape of diagnostic and personalized medicine will shift with the introduction of new omics technology, which would enable early diagnosis and customized therapy. Additionally, more research on marine life and other therapeutic plants could help find antifungals with extremely little chance of developing resistance. Since the abuse of antifungals in agriculture is intimately linked to the development of resistance in human infections, it is equally necessary to address this issue. Establishing it as a standard will need international participation from researchers, clinical scientists, and politicians to improve diagnosis, create monitoring systems, and provide fair access to therapies that may arise in the real world. Campaigns to raise awareness of the rising threat of fungal infection highlight the need for more research and infrastructure investment in the health sector. The spread of fungal illnesses will make the urgent need for commitment, creativity, and international collaboration in public health even more pressing if the risks are not immediately addressed.

REFERENCE

1. Bongomin F, Gago S, Oladele R, Denning D. Global and multinational prevalence of fungal diseases: estimate precision. J Fungi. 2017;3:57. https://doi.org/10.3390/jof3040057.
2. Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20:557–71. https://doi.org/10.1038/s41579-022-00720-1.
3. Lee Y, Puumala E, Robbins N, Cowen LE. Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond. Chem Rev. 2021;121:3390 411. https://doi.org/10.1021/acs.chemrev.0c00199.
4. Burki T. WHO publishes fungal priority pathogens list. Lancet Microbe. 2023;4:e74. https://doi.org/10.1016/S2666-5247(23)00003-4.
5. World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action. 2022. Available from: https://www.who.int/publications/i/item/9789240060241.
6. Badiee P, Hashemizadeh Z. Opportunistic invasive fungal infections: diagnosis & clinical management. Indian J Med Res. 2014;139(2):195–204.
7. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multinational prevalence of fungal diseases—estimate precision. J Fungi (Basel). 2017;3(4):57. https://doi.org/10.3390/jof3040057.
8. Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014;5(1):161–9. https://doi.org/10.4161/viru.26187.
9. Havlickova B, Czaika VA, Friedrich M. Epidemiological trends in skin mycoses worldwide. Mycoses. 2008;51(Suppl 4):2–15. https://doi.org/10.1111/j.1439-0507.2008.01606.x.
10. Christenson JK, Peterson GM, Naunton M, Bushell M, Kosari S, Baby KE, et al. Challenges and opportunities in the management of onychomycosis. J Fungi. 2018;4(3):87. https://doi.org/10.3390/jof4030087.
11. Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: recent trends and therapeutic implications. Fungal Genet Biol. 2019;132:103255.

12. Piraccini BM, Rech G, Tosti A. Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol. 2008;59(5 Suppl):S75–6.
13. Schwartz IS. The emerging threat of antifungal resistance in transplant infectious diseases. Curr Infect Dis Rep. 2018;20:3. https://doi.org/10.1007/s11908-018-0608-y.
14. Hendrickson J, Hu C, Aitken S. Antifungal resistance: a concerning trend for the present and future. Curr Infect Dis Rep. 2019;21:47. https://doi.org/10.1007/s11908-019-0702-9.
15. Azevedo MM, Faria-Ramos I, Cruz LC, Pina-Vaz C, Gonçalves RA. Genesis of azole antifungal resistance from agriculture to clinical settings. J Agric Food Chem. 2015;63(34):7463–8.
16. Berger S, Chazli Y El, Babu A. Azole resistance in Aspergillus fumigatus: a consequence of antifungal use in agriculture? Front Microbiol. 2017;8:1024. https://doi.org/10.3389/fmicb.2017.01024.
17. Burks C, Darby A, Gómez Londoño L, Momany M, Brewer MT. Azole-resistant Aspergillus fumigatus in the environment: Identifying key reservoirs and hotspots of antifungal resistance. PLoS Pathog. 2021;17(7):e1009711.
18. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis. 2013;56(12):1724–32.
19. Meis JF, Chowdhary A, Rhodes JL, Fisher MC, Verweij PE. Clinical implications of globally emerging azole resistance in Aspergillus fumigatus. Philos Trans R Soc B Biol Sci. 2016;371(1709):20150460.
20. Schwartz IS, Patterson TF. The emerging threat of antifungal resistance in transplant infectious diseases. Curr Infect Dis Rep. 2018;20:2.
21. Ader F, Nseir S, Le Berre R, Leroy S, Tillie-Leblond I, Marquette CH, et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease: an emerging fungal pathogen. Clin Microbiol Infect. 2005;11(6):427–9.
22. Posteraro B, Torelli R, de Carolis E, Posteraro P, Sanguinetti M. Update on the laboratory diagnosis of invasive fungal infections. Mediterr J Hematol Infect Dis. 2011;3(1):e2011002.
23. Kontoyiennis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091–100.
24. Gintjee TJ, Donnelley MA, Thompson GR. Aspiring antifungals: review of current antifungal pipeline developments. J Fungi. 2020;6(1):28.
25. Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–60.
26. Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ. Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science. 2018;360(6390):739–42.
27. Parapouli M, Vasileiadi A, Afendra AS, Hatziloukas E. Saccharomyces cerevisiae and its industrial applications. AIMS Microbiol. 2020;6(1):1–32.
28. Tollemar J. Need for alternative trial designs and evaluation strategies for therapeutic studies of invasive mycoses. Clin Infect Dis. 2001;33(1):95–106.
29. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no

ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1–12.
30. El-Hossary EM, Cheng C, Hamed MM, El-Sayed Hamed AN, Ohlsen K, Hentschel U, et al. Antifungal potential of marine natural products. [Journal details missing].
31. Vitali A. Antimicrobial peptides derived from marine sponges. Am J Clin Microbiol Antimicrob. 2018;1:1006.
32. De Leo M, Braca A, De Tommasi N, Norscia I, Morelli I, Battinelli L, et al. Phenolic compounds from Baseonema acuminatum leaves: Isolation and antimicrobial activity. Planta Med. 2004;70:841–6.
33. Rubio OC, Cuellar AC, Rojas N, Castro HV, Rastrelli L, Aquino R. A polyisoprenylated benzophenone from Cuban propolis. J Nat Prod. 1999;62:1013–5.
34. Dharmaratne HR, Piyasena KG, Tennakoon SB. A geranylated biphenyl derivative from Garcinia malvgostana. Nat Prod Res. 2005;19:239–43.
35. Nkunya MH, Makangara JJ, Jonker SA. Prenylindoles from Tanzanian Monodora and Isolona species. Nat Prod Res. 2004;18:253–8.
36. Lee DG, Park Y, Kim MR, Jung HJ, Seu YB, Hahm KS, et al. Antifungal effects of phenolic amides isolated from the root bark of Lycium chinense. Biotechnol Lett. 2004;26:1125–30.
37. Perry NB, Brennan NJ. Antimicrobial and cytotoxic phenolic glycoside esters from the New Zealand tree Toronia toru. J Nat Prod. 1997;60:623–6.
38. Tan RX, Lu H, Wolfender JL, Yu TT, Zheng WF, Yang L, et al. Mono- and sesquiterpenes and antifungal constituents from Artemisia species. Planta Med. 1999;65:64–7.
39. Bylka W, Szaufer-Hajdrych M, Matławska I, Goślińska O. Antimicrobial activity of isocytisoside and extracts of Aquilegia vulgaris L. Lett Appl Microbiol. 2004;39:93–7.
40. Rao MS, Duddeck H, Dembinski R. Isolation and structural elucidation of 3,4',5,7-tetraacetyl quercetin from Adina cordifolia (Karam Ki Gaach). Fitoterapia. 2002;73:353–5.
41. Meragelman TL, Tucker KD, McCloud TG, Cardellina JH 2nd, Shoemaker RH. Antifungal flavonoids from Hildegardia barteri. J Nat Prod. 2005;68:1790–2.
42. Klausmeyer P, Chmurny GN, McCloud TG, Tucker KD, Shoemaker RH. A novel antimicrobial indolizinium alkaloid from Aniba panurensis. J Nat Prod. 2004;67:1732–5.
43. Singh NV, Azmi S, Maurya S, Singh UP, Jha RN, Pandey VB. Two plant alkaloids isolated from Corydalis longipes as potential antifungal agents. Folia Microbiol (Praha). 2003;48:605–9.
44. Posch W, Wilflingseder D, Lass-Flörl C. Immunotherapy as an antifungal strategy in immune compromised hosts. Current Clinical Microbiology Reports. 2020 Sep;7:57-66.
45. Rachini A, Pietrella D, Lupo P, Torosantucci A, Chiani P, Bromuro C, Proietti C, Bistoni F, Cassone A, Vecchiarelli A. An anti-β-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo. Infection and immunity. 2007 Nov;75(11):5085-94.
46. Di Mambro T, Vanzolini T, Bruscolini P, Perez-Gaviro S, Marra E, Roscilli G, Bianchi M, Fraternale A, Schiavano GF, Canonico B, Magnani M. A new humanized antibody is effective against pathogenic fungi in vitro. Scientific Reports. 2021 Sep 30;11(1):19500.
47. Nosanchuk JD, Dadachova E. Radioimmunotherapy of fungal diseases: the therapeutic potential of cytocidal radiation delivered by antibody targeting fungal cell surface antigens. Frontiers in Microbiology. 2012 Jan 12;2:283.

48. Casadevall A, Pirofski LA. Adjunctive immune therapy for fungal infections. Clin Infect Dis. 2001;33:1048–56.
49. Valedkarimi Z, Nasiri H, Aghebati-Maleki L, Majidi J. Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy. Biomed Pharmacother. 2017;95:731–42.
50. Datta K, Hamad M. Immunotherapy of fungal infections. Immunol Invest. 2015;44(8):738–76.
51. Hussain S. Immunization and vaccination. In: Psychiatry of Pandemics: A Mental Health Response to Infection Outbreak. Springer; 2019. p. 153–77.
52. Hernández-Chávez MJ, Pérez-García LA, Niño-Vega GA, Mora-Montes HM. Fungal strategies to evade the host immune recognition. J Fungi. 2017;3:51.
53. Scorzoni L, de Paula ESilva AC, Marcos CM, Assato PA, de Melo WC, de Oliveira HC, et al. Antifungal therapy: New advances in the understanding and treatment of mycosis. Front Microbiol. 2017;8:36.
54. Tesfahuneygn G, Gebreegziabher G. Development of vaccination against fungal disease: A review article. Int J Trop Dis. 2018;1:005.
55. Hamad M. Universal fungal vaccines: Could there be light at the end of the tunnel? Hum Vaccin Immunother. 2012;8:1758–63.
56. Pattison HT, Millar BC, Moore JE. Fungal vaccines. Br J Biomed Sci. 2021;78:167–76.
57. Oliveira LVN, Wang R, Specht CA, Levitz AM. Vaccines for human fungal diseases: Close but still a long way to go. NPJ Vaccines. 2021;6:33.
58. Edwards JE Jr, Schwartz MM, Schmidt CS, Sobel JD, Nyirjesy P, Schodel F, et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis—A phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2018;66:1928–36.
59. Normile TG, Chu T, Sheridan BS, Del Poeta M. Vaccine protection by Cryptococcus neoformans Δsgl1 is mediated by γδ T cells via TLR2 signaling. Mucosal Immunol. 2022;15:1416–30.
60. Singh S, Nabeela S, Barbarino A, Ibrahim AS, Uppuluri P. Antibodies targeting Candida albicans Als3 and Hyr1 antigens protect neonatal mice from candidiasis. Front Immunol. 2022;12:925821.
61. Rivera A, Lodge J, Xue C. Harnessing the immune response to fungal pathogens for vaccine development. Annu Rev Microbiol. 2002;76:703–26.
62. Hamad M. Antifungal immunotherapy and immunomodulation: A double-hitter approach to deal with invasive fungal infections. Scand J Immunol. 2008;67(6):533–43.
63. Aghebati-Maleki L, Bakhshinejad B, Baradaran B, Motallebnezhad M, Aghebati-Maleki A, Nickho H, et al. Phage display as a promising approach for vaccine development. J Biomed Sci. 2016;23(1):66.
64. Hyde KD, Baldrian P, Chen Y, Chethana KWT, De Hoog S, Doilom M, et al. Current trends, limitations and future research in the fungi. Fungal Divers. 2024;125:1–71.
65. Wijayawardene NN, Boonyuen N, Ranaweera CB, de Zoysa HKS, Padmathilake RE, Nifla F, et al. OMICS and other advanced technologies in mycological applications. J Fungi. 2023;9:688.
66. Ball B, Langille M, Geddes-McAlister J. Fun(gi)omics: Advanced and diverse technologies to explore emerging fungal pathogens and define mechanisms of antifungal resistance. mBio. 2020;11:e01020-20.
67. Al Jindan R, AlEraky DM, Farhat M, Almandil NB, AbdulAzeez S, Borgio JF. Genomic insights into virulence factors and multi-drug resistance in Clostridium perfringens IRMC2505A. Toxins. 2023;15:359.

68. Champer J, Ito JI, Clemons KV, Stevens DA, Kalkum M. Proteomic analysis of pathogenic fungi reveals highly expressed conserved cell wall proteins. J Fungi. 2016;2:6.
69. Li G, Jian T, Liu X, Lv Q, Zhang G, Ling J. Application of metabolomics in fungal research. Molecules. 2022;27:7365.
70. Subramanian I, Verma S, Kumar S, Jere A, Anamika K. Multi-omics data integration, interpretation, and its application. Bioinform Biol Insights. 2020;14:1177932219899051.
71. Cheng SC, Quintin J, Cramer RA, Shepardson KM, Saeed S, Kumar V, et al. mTOR- and HIF-1α-mediated aerobic glycolysis as metabolic basis for trained immunity. Science. 2014;345:1250684.
72. Saeed S, Quintin J, Kerstens HHD, Rao NA, Aghajanirefah A, Matarese F, et al. Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity. Science. 2014;345:1251086.
73. de Jesús-Gil C, Sans-de San Nicolàs L, Ruiz-Romeu E, Ferran M, Soria-Martínez L, García-Jiménez I, et al. Interplay between humoral and CLA+ T cell response against Candida albicans in psoriasis. Int J Mol Sci. 2021;22:1519.
74. Stuehler C, Nowakowska J, Bernardini C, Topp MS, Battegay M, Passweg J, et al. Multispecific Aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections. J Infect Dis. 2015;211:1251–61.
75. Leitão JH, Rodríguez-Ortega MJ. Omics and bioinformatics approaches to identify novel antigens for vaccine investigation and development. Vaccines. 2020;8:653.
76. Hudson WH, Wieland A. Technology meets TILs: Deciphering T cell function in the -omics era. Cancer Cell. 2023;41:41–57.
77. Dai X, Shen L. Advances and trends in omics technology development. Front Med. 2022;9:911861.
78. Bianconi I, Aschbacher R, Pagani E. Current uses and future perspectives of genomic technologies in clinical microbiology. Antibiotics. 2023;12:1580.